PD-L1蛋白在鼻咽癌中的表达及其临床意义

Expression and clinical significance of PDL1 protein in nasopharyngeal carcinoma

摘要:

目的探讨PDL1在鼻咽癌中的表达及其临床意义。方法采用免疫组织化学技术对收集的162例鼻咽癌组织进行PDL1蛋白的表达检测，并结合患者临床病理参数及预后信息，探讨其临床价值。结果PDL1蛋白表达水平与性别、年龄、PS评分、临床分期、吸烟情况等临床病理参数之间无显著差异(P>0.05)。PDL1阳性组与阴性组3年总生存率分别为92.3%与80.0%，差异具有统计学意义(P=0.026)。结论PDL1蛋白阳性鼻咽癌患者预后较好，有望成为鼻咽癌患者预后评估的生物标志物。

Abstract:

ObjectiveTo investigate the expression and clinical significance of programmed deathligand 1 (PDL1) protein in nasopharyngeal carcinoma (NPC).MethodsImmunohistochemistry was used to detect the expression of PDL1 in 162 NPC specimens. The relationship between PDL1 expression and clinicopathological characteristics of NPC was further explored.ResultsThe results showed that no significant relationship existed between PDL1 expression and clinicopathological parameters such as patients’ gender, age, PS score, and smoking status as well as clinical stage of the tumor (all P>0.05). The 3year overall survival rate in PDL1 positive group was much higher than that in PDL1 negative group (92.3% vs 80.0%, P=0.026).ConclusionNPC patients with positive PDL1 expression show better prognosis than those with negative PDL1 expression, which indicates that PDL1 may be a potential biomarker for the prediction of prognosis in patients with NPC.